Clinical Characteristics and Risk Prediction Score in Patients With Mild-to-Moderate Coronavirus Disease 2019 in Japan
Open Access
- 6 November 2022
- journal article
- research article
- Published by Springer Nature in Cureus
- Vol. 14 (11) , e31210
Abstract
Background: Coronavirus disease 2019 (COVID-19) has rapidly spread worldwide, causing widespread mortality. Many patients with COVID-19 have been treated in homes, hotels, and medium-sized hospitals where doctors were responsible for assessing the need for critical care hospitalization. This study aimed to establish a severity prediction score for critical care triage. Method: We analyzed the data of 368 patients with mild-to-moderate COVID-19 who had been admitted to Fussa Hospital, Japan, from April 2020 to February 2022. We defined a high-oxygen group as requiring ≥4 l/min of oxygen. Multivariable logistic regression was used to construct a risk prediction score, and the best model was selected using a stepwise selection method. Results: Multivariable analysis showed that older age (≥70 years), elevated creatine kinase (≥127 U/L), C-reactive protein (≥2.19 mg/dL), and ferritin (≥632.7 ng/mL) levels were independent risk factors associated with the high-oxygen group. Each risk factor was assigned a score ranging from 0 to 4, and we referred to the final overall score as the Fussa score. Patients were classified into two groups, namely, high-risk (total risk factors, ≥2) and low-risk (total risk score, < 0.0001). Conclusions: The Fussa score might help to identify patients with COVID-19 who require critical care hospitalization.Keywords
This publication has 19 references indexed in Scilit:
- Development of a Risk Prediction Score to Identify High-Risk Groups for the Critical Coronavirus Disease 2019 (COVID-19) in JapanJapanese Journal of Infectious Diseases, 2021
- Clinical characteristics and antibiotics treatment in suspected bacterial infection patients with COVID-19International Immunopharmacology, 2021
- Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysisClinical Microbiology and Infection, 2020
- Remdesivir for the Treatment of Covid-19 — Final ReportNew England Journal of Medicine, 2020
- Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality ScoreBMJ, 2020
- AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical TrialClinical Infectious Diseases, 2020
- The COVID-19 Pandemic in JapanSurgery Today, 2020
- Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trialThe Lancet, 2020
- A Novel Coronavirus from Patients with Pneumonia in China, 2019New England Journal of Medicine, 2020
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statisticsBone Marrow Transplantation, 2012